Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study

Completed · Phase 2

Conditions studied: Epithelial Ovarian Cancer

In brief

The purpose of this trial is to assess the safety profile of Cvac for epithelial ovarian cancer patients who were enrolled in the Cvac clinical trial CAN-003 and are no longer eligible for study participation due to disease progression.

Key facts

Study ID
NCT01617629
Run by
Prima BioMed Ltd
People needed
9
Starts
2011-12-01
Expected to finish
2014-04-01
Last updated by the study team
2017-12-08

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.